Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Cell Cycle-dependent
100%
Antitumor Effect
100%
Sorafenib
100%
Apoptosis Induction
18%
Tumor Growth Delay
18%
Phosphorylation
9%
Mechanism of Action
9%
Tyrosine Kinase
9%
Anticancer Activity
9%
Gastrointestinal Tract
9%
Malignancy
9%
Molecular Targets
9%
Cyclin D1 (CCND1)
9%
Myeloid Cell leukemia-1 (Mcl-1)
9%
Radiation Therapy
9%
Cell Cycle Progression
9%
Anti-angiogenesis
9%
Colony Formation Assay
9%
Colony Size
9%
Radiation Response
9%
Antineoplastic Drugs
9%
Multikinase Inhibitor
9%
B-Raf
9%
Clinical Testing
9%
Cytostasis
9%
Viability Assay
9%
Xenograft Tumor Growth
9%
Human Tumor Cell Lines
9%
Serine/threonine Kinase
9%
Medicine and Dentistry
Cell Cycle
100%
Sorafenib
100%
Tumor Progression
18%
Programmed Cell Death
18%
In Vitro
9%
Cell Line
9%
Phosphotransferase Inhibitor
9%
Cancer
9%
Protein Tyrosine Kinase
9%
Cyclin D1
9%
Colony Formation
9%
Anticarcinogen
9%
Xenograft
9%
Protein Serine Threonine Kinase
9%
Antiangiogenic Activity
9%
Cell Cycle Progression
9%
Tumor Cell Line
9%
Radiosensitivity
9%
Radiation Therapy
9%
Radiation Response
9%
Radiation Treatment
9%
phosphorylation
9%
Immunology and Microbiology
Cell Cycle
100%
Sorafenib
100%
Programmed Cell Death
18%
Phosphotransferase
18%
Kinase
18%
Cell Line
9%
Tumor Cell Line
9%
Colony Formation
9%
Cyclin D1
9%
Cell Cycle Progression
9%
Antiangiogenic Activity
9%
Xenograft
9%
Serine
9%
Tyrosine
9%
Threonine
9%
Radioresistance
9%
Cytostasis
9%
In Vitro
9%
phosphorylation
9%
Biochemistry, Genetics and Molecular Biology
Cell Cycle
100%
Sorafenib
100%
Kinase
18%
Phosphotransferase
18%
Tumor Progression
18%
Programmed Cell Death
18%
Tyrosine
9%
Anticancer
9%
Cyclin D1
9%
Colony Formation
9%
Cell Cycle Progression
9%
Antiangiogenic Activity
9%
Cytostasis
9%
Radiosensitivity
9%
Serine
9%
Threonine
9%
phosphorylation
9%
Pharmacology, Toxicology and Pharmaceutical Science
Sorafenib
100%
Tumor Growth
18%
Neoplasm
9%
Protein Tyrosine Kinase
9%
Anticarcinogen
9%
Molecular Target
9%
Cyclin D1
9%
Phosphotransferase Inhibitor
9%
Protein Serine Threonine Kinase
9%
Viability Assay
9%